A bedside cardiovascular-drug curriculum that separates rate control, rhythm control, vasodilation and anti-impulse therapy. The goal is not to memorize drug lists—it is to choose the agent that matches rhythm mechanism, ventricular function, blood pressure, ischemia and the end-organ emergency.
Select adenosine, beta blockade, amiodarone, lidocaine or magnesium from the rhythm mechanism rather than from monitor appearance alone.
Match nicardipine/clevidipine, labetalol/esmolol, nitroglycerin and nitroprusside to the hypertensive emergency phenotype.
Use anti-impulse therapy before pure vasodilation in acute aortic syndromes when physiology permits.
Recognize when tachyarrhythmia is compensatory and drug-induced rate reduction can worsen low-output shock.
Treat torsades as a magnesium/electrical-instability problem rather than generic monomorphic VT.
The table below is a selection framework. Open the individual monograph for exact dosing, preparation, renal/CRRT/IHD adjustment, interactions and evidence traceability.
ICU role: AV-nodal blocker used diagnostically/therapeutically for regular narrow-complex AV-node-dependent SVT.
Monitor: Continuous ECG and resuscitation readiness.
ICU role: Broad antiarrhythmic for selected ventricular and atrial arrhythmias, especially when structural heart disease limits alternatives.
Monitor: ECG/QT, BP/HR, K/Mg; liver/thyroid/lung with longer courses.
ICU role: Class Ib sodium-channel blocker for selected ventricular arrhythmias, particularly ischemia-associated VT/VF.
Monitor: Rhythm, neurologic status, liver function/exposure.
ICU role: First-line pharmacologic therapy for torsades/long-QT polymorphic VT and a core electrolyte correction drug.
Monitor: ECG, renal function, Mg exposure and recurrence.
ICU role: Ultra-short beta-1 blocker for rapidly titratable rate/impulse control.
Monitor: Continuous BP/HR, perfusion and ventricular function.
ICU role: Combined alpha/beta blocker for hypertensive emergencies and pregnancy/postpartum severe hypertension.
Monitor: BP/HR, bronchospasm, perfusion.
ICU role: Titrated IV dihydropyridine vasodilator for many neurologic and general hypertensive emergencies.
Monitor: Continuous BP, HR, neurologic/end-organ response.
ICU role: Ultra-short IV dihydropyridine for rapidly titratable arterial BP control.
Monitor: Continuous BP/HR, triglyceride/lipid exposure for prolonged use.
ICU role: Venodilator/vasodilator especially useful for ischemic pulmonary edema and high-afterload SCAPE physiology.
Monitor: BP, symptoms/ischemia, pulmonary edema response.
ICU role: Potent balanced arterial/venous vasodilator for selected severe afterload-driven crises.
Monitor: Arterial BP, acid-base/lactate when prolonged/high dose, renal/hepatic status.
| Agent | ICU role | Why I choose it | Why I hesitate | What I monitor |
|---|---|---|---|---|
| Adenosine Endogenous Purine Nucleoside / AV Nodal Blocking Agent | AV-nodal blocker used diagnostically/therapeutically for regular narrow-complex AV-node-dependent SVT. | ✓ Very short half-life makes it ideal for stable regular SVT when the rhythm fits AVNRT/AVRT. | ✕ Avoid reflex use in irregular wide-complex tachycardia or pre-excited AF; transient bronchospasm can matter in severe reactive airway disease. | Continuous ECG and resuscitation readiness. |
| Amiodarone Class III Antiarrhythmic (Multi-Channel Blocker) | Broad antiarrhythmic for selected ventricular and atrial arrhythmias, especially when structural heart disease limits alternatives. | ✓ Useful for recurrent VT/VT storm as part of a broader electrical-storm strategy and for selected atrial rhythm control. | ✕ Hypotension/bradycardia acutely; long-term thyroid, lung and liver toxicity. It is not the answer to torsades from prolonged QT. | ECG/QT, BP/HR, K/Mg; liver/thyroid/lung with longer courses. |
| Lidocaine IV Class Ib antiarrhythmic | Class Ib sodium-channel blocker for selected ventricular arrhythmias, particularly ischemia-associated VT/VF. | ✓ Useful alternative/adjunct in recurrent ventricular arrhythmia when the phenotype fits and amiodarone is ineffective or undesirable. | ✕ Neurotoxicity rises with accumulation; do not use as a generic therapy for toxin-induced sodium-channel blockade without toxicology guidance. | Rhythm, neurologic status, liver function/exposure. |
| Magnesium Sulfate Electrolyte / Multi-Mechanism Membrane & Neuromuscular Modulator | First-line pharmacologic therapy for torsades/long-QT polymorphic VT and a core electrolyte correction drug. | ✓ Give for torsades even if the measured magnesium is normal. | ✕ Does not replace defibrillation for instability or treatment of the cause/QT-prolonging drug. | ECG, renal function, Mg exposure and recurrence. |
| Esmolol Ultra-Short-Acting Cardioselective Beta-1 Blocker | Ultra-short beta-1 blocker for rapidly titratable rate/impulse control. | ✓ Useful when beta blockade is desirable but tolerance is uncertain—e.g., aortic dissection or selected tachyarrhythmia. | ✕ Can precipitate shock in decompensated low-output states; bronchospasm/bradycardia/heart block remain concerns. | Continuous BP/HR, perfusion and ventricular function. |
| Labetalol Combined Alpha-1 and Non-Selective Beta Blocker | Combined alpha/beta blocker for hypertensive emergencies and pregnancy/postpartum severe hypertension. | ✓ Useful when heart-rate control plus BP reduction are both desirable and bronchospasm/bradycardia are absent. | ✕ Avoid or use great caution with asthma, bradycardia, heart block and decompensated pump failure. | BP/HR, bronchospasm, perfusion. |
| Nicardipine Dihydropyridine Calcium Channel Blocker | Titrated IV dihydropyridine vasodilator for many neurologic and general hypertensive emergencies. | ✓ Smooth titratability is useful when BP must be lowered without beta blockade. | ✕ Reflex tachycardia/volume load; it does not provide anti-impulse control for aortic dissection by itself. | Continuous BP, HR, neurologic/end-organ response. |
| Clevidipine Ultra-Short-Acting Dihydropyridine Calcium Channel Blocker | Ultra-short IV dihydropyridine for rapidly titratable arterial BP control. | ✓ Fast onset/offset when minute-to-minute BP control matters. | ✕ Lipid emulsion load/formulation issues and reflex tachycardia; no beta-blocking effect. | Continuous BP/HR, triglyceride/lipid exposure for prolonged use. |
| Nitroglycerin Venous Vasodilator & Organic Nitrate | Venodilator/vasodilator especially useful for ischemic pulmonary edema and high-afterload SCAPE physiology. | ✓ Rapid preload/afterload reduction in hypertensive pulmonary edema when BP is adequate. | ✕ Avoid with hypotension, RV preload dependence and recent PDE-5 inhibitor exposure. | BP, symptoms/ischemia, pulmonary edema response. |
| Nitroprusside Direct Arterial & Venous Vasodilator | Potent balanced arterial/venous vasodilator for selected severe afterload-driven crises. | ✓ Useful when rapid major afterload reduction is required and monitoring is intensive. | ✕ Cyanide/thiocyanate toxicity, coronary steal concerns and profound hypotension; renal/hepatic failure increases toxicity risk. | Arterial BP, acid-base/lactate when prolonged/high dose, renal/hepatic status. |
Why: Adenosine can terminate AVNRT/orthodromic AVRT and can clarify atrial activity because of its very short AV-nodal effect.
Why: Blocking the AV node can facilitate conduction down an accessory pathway and precipitate VF.
Why: Impulse control reduces dP/dt and aortic wall stress; afterload reduction alone can provoke reflex tachycardia.
Why: SCAPE is dominated by acute afterload/redistribution physiology; fast vasodilation can be more important than early net fluid removal.
Recognition becomes selection, then organ-failure adjustment, competing physiology and senior-level prioritization.
Regular narrow-complex tachycardia 185/min, BP 118/72, no ischemia or pulmonary edema.
Use vagal maneuvers and adenosine if AV-node-dependent SVT is likely, with continuous ECG and resuscitation readiness.
Polymorphic VT twisting around the baseline after QT prolongation; pulse present but unstable.
Defibrillate if unstable and give IV magnesium while stopping QT-prolonging causes and correcting potassium. Do not treat classic torsades as routine monomorphic VT with amiodarone.
CTA confirms type A dissection. HR 122, SBP 205, severe pain.
Analgesia plus rapid beta-blockade/anti-impulse therapy when tolerated, then add titratable vasodilation to reach the surgical-team BP target while arranging emergent repair.
Recurrent monomorphic VT after MI despite shocks; K/Mg corrected and patient is increasingly adrenergic.
Use a comprehensive electrical-storm strategy: antiarrhythmic therapy such as amiodarone, sympathetic suppression (often beta blockade when tolerated), sedation, ischemia evaluation and early EP/ablation planning—not repeated shocks alone.
AF 145/min, EF 15%, cold extremities, lactate 6, MAP 58 on norepinephrine. The team wants aggressive beta blockade for rate control.
Stabilize the shock and decide whether AF is driver or compensation. Avoid reflex long-acting beta blockade in profound low-output physiology; consider synchronized cardioversion if instability is rhythm-mediated or a hemodynamically tolerable rhythm strategy while supporting perfusion.
Ultra-short-acting agent that transiently blocks AV nodal conduction to terminate AV-node-dependent reentrant SVT — its sub-10-second half-life makes the rapid-push-plus-immediate-flush administration technique as important as th…
Broad-spectrum antiarrhythmic used for shock-refractory cardiac arrest, stable ventricular arrhythmias, and rate/rhythm-related management of atrial fibrillation — notable for an extremely long half-life and cumulative multi-orga…
IV sodium-channel blocker used for refractory ventricular arrhythmias and as an alternative to amiodarone in shock-refractory VF/pVT.
Spans four genuinely distinct ICU indications — torsades de pointes, adjunctive severe asthma therapy, eclampsia/severe preeclampsia, and simple hypomagnesemia repletion — each with its own mechanism-relevant dosing; no single do…
Ultra-short-acting selective beta-1 blocker cleared by red blood cell esterases (half-life 9 min) for rapid control of supraventricular tachycardia and aortic dissection shear stress.
Combined alpha-1 and beta-1/beta-2 blocker (1:7 alpha:beta ratio IV) for hypertensive emergencies, stroke, and aortic dissection — lowers BP and HR simultaneously.
Potent intravenous arterial vasodilator for acute hypertensive emergencies, intracerebral hemorrhage (ICH), and stroke — highly selective arterial vasodilation with minimal venodilation or cardiodepression.
Ultra-short-acting IV arterial vasodilator cleared by blood esterases (half-life 1 min) for precise titratable blood pressure control in acute hypertensive emergencies.
Predominant venodilator for Acute Coronary Syndrome (ACS) and Acute Cardiogenic Pulmonary Edema — reduces cardiac preload and myocardial oxygen demand, but causes nitrate tolerance.
Potent direct arterial and venous vasodilator for severe hypertensive emergencies and acute mitral regurgitation — risks cyanide and thiocyanate toxicity with high doses or renal failure.
This Masterclass teaches selection and reasoning. Exact dosing, concentration, infusion preparation, renal/hepatic/RRT adjustment and monitoring must be checked in the linked medication monograph and the institution's current formulary/protocol. Local resistance patterns and regulatory drug availability can change faster than a static teaching page.